NASDAQ:YS YS Biopharma (YS) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free YS Stock Alerts $0.80 +0.01 (+1.27%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.77▼$0.8550-Day Range$0.38▼$0.9452-Week Range$0.35▼$1.97Volume39,764 shsAverage Volume194,929 shsMarket Capitalization$74.45 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get YS Biopharma alerts: Email Address YS Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside556.3% Upside$5.25 Price TargetShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector385th out of 908 stocksPharmaceutical Preparations Industry174th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingYS Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageYS Biopharma has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.53% of the float of YS Biopharma has been sold short.Short Interest Ratio / Days to CoverYS Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in YS Biopharma has recently decreased by 1.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldYS Biopharma does not currently pay a dividend.Dividend GrowthYS Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YS. Previous Next 2.4 News and Social Media Coverage News SentimentYS Biopharma has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for YS Biopharma this week, compared to 1 article on an average week.Search Interest2 people have searched for YS on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, YS Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of YS Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for YS Biopharma are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Book Value per Share RatioYS Biopharma has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About YS Biopharma Stock (NASDAQ:YS)YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.Read More YS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YS Stock News HeadlinesApril 26, 2024 | americanbankingnews.comDiamond Equity Equities Analysts Decrease Earnings Estimates for YS Biopharma Co., Ltd. (NASDAQ:YS)April 22, 2024 | finance.yahoo.comYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call TranscriptApril 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | markets.businessinsider.comYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024April 19, 2024 | prnewswire.comYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 18, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineApril 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 18, 2024 | prnewswire.comYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineApril 18, 2024 | americanbankingnews.comYS Biopharma (YS) Set to Announce Quarterly Earnings on FridayApril 16, 2024 | finance.yahoo.comYS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024April 9, 2024 | msn.comChinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved CompetitorApril 9, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 9, 2024 | finance.yahoo.comYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 9, 2024 | prnewswire.comYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 3, 2024 | finance.yahoo.comYS Biopharma Announces Full Repayment of US$40,000,000 Loan FacilityMarch 28, 2024 | msn.comTechnology and demographics affect hiring and pay strategiesMarch 5, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesMarch 5, 2024 | finance.yahoo.comYS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesFebruary 22, 2024 | finance.yahoo.comYS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024February 17, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 17, 2024 | finance.yahoo.comYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 16, 2024 | prnewswire.comYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 16, 2024 | finance.yahoo.comShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.February 16, 2024 | prnewswire.comShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.February 14, 2024 | finance.yahoo.comYS Biopharma Announces Appointment of New DirectorsSee More Headlines Receive YS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for YS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:YS CUSIPN/A CIK1946399 Webwww.ysbiopharm.com Phone852-2155-7212FaxN/AEmployees754Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$5.25 Low Stock Price Target$5.25 Potential Upside/Downside+556.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.65 Current Ratio1.41 Quick Ratio1.09 Sales & Book Value Annual Sales$100 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.70Miscellaneous Outstanding Shares93,060,000Free FloatN/AMarket Cap$74.45 million OptionableNot Optionable Beta0.53 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Gang Li (Age 42)Head of Marketing & Sales Dr. Yuan Liu Ph.D. (Age 37)Head of Vaccine Research Dr. Hui Shao Ph.D. (Age 56)President, CEO & Executive Director Ms. Chunyuan Wu CPA (Age 46)Chief Financial Officer & Director Dr. Zenaida Reynoso Mojares (Age 65)Chief Medical Officer Key CompetitorsAffimedNASDAQ:AFMDConnect BiopharmaNASDAQ:CNTBAssertioNASDAQ:ASRTAssembly BiosciencesNASDAQ:ASMBCorvus PharmaceuticalsNASDAQ:CRVSView All CompetitorsInstitutional OwnershipSuperstring Capital Management LPBought 307,920 shares on 2/14/2024Ownership: 0.331%View All Institutional Transactions YS Stock Analysis - Frequently Asked Questions Should I buy or sell YS Biopharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for YS Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" YS shares. View YS analyst ratings or view top-rated stocks. What is YS Biopharma's stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for YS Biopharma's stock. Their YS share price targets range from $5.25 to $5.25. On average, they anticipate the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 556.3% from the stock's current price. View analysts price targets for YS or view top-rated stocks among Wall Street analysts. How have YS shares performed in 2024? YS Biopharma's stock was trading at $0.5110 at the beginning of the year. Since then, YS stock has increased by 56.6% and is now trading at $0.80. View the best growth stocks for 2024 here. Are investors shorting YS Biopharma? YS Biopharma saw a decline in short interest in March. As of March 31st, there was short interest totaling 96,900 shares, a decline of 17.0% from the March 15th total of 116,800 shares. Based on an average trading volume of 211,800 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the company's stock are sold short. View YS Biopharma's Short Interest. How do I buy shares of YS Biopharma? Shares of YS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:YS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
